CAS: 20511-12-0; 5-Iodopyridin-2-Amine

相似化合物

375853-79-5 23597-15-1 104830-06-0

上下游产品

CAS号504-29-0 2-氨基吡啶 | CAS号1072-97-5 2-氨基-5-溴吡啶 | CAS号157020-27-4 pyridinium N-[2... | CAS号110-86-1 吡啶 | CAS号1600-27-7 乙酸汞 | CAS号7553-56-2 碘 | CAS号33421-40-8 2-氨基-5-苯基吡啶 | CAS号351019-18-6 6-氟-3-吡啶硼酸 | CAS号470463-36-6 N-(5-碘-吡啶-2-基)-... | CAS号375853-79-5 2-(B°C-氨基)-5-碘吡啶 | CAS号444120-94-9 2-氯-5-(4,4,5,5-... | CAS号444120-95-0 2-氟吡啶-5-硼酸频哪醇酯 | CAS号426825-75-4 6-碘H-咪唑[1,2-A]吡啶 | CAS号444120-91-6 6-氯吡啶-3-硼酸 | CAS号4214-73-7 2-氨基-5-氰基吡啶 | CAS号171197-80-1 2-氟-5-碘吡啶

2-氨基吡啶置于硫酸,碘,过碘酸体系中,用 水,溶剂黄146 用作溶剂,以68%的收率获得2-氨基-5-碘吡啶
参考文献:通过改良的 Negishi 交叉偶联反应合成不同双取代的 2,2'-联吡啶
标题:通过改良的 Negishi 交叉偶联反应合成不同双取代的 2,2'-联吡啶
摘要:已经开发了通过应用改良的 Negishi 交叉偶联条件从取代的 2-溴-和 2-氯吡啶中获得许多不同二取代的 2,2'-联吡啶的通用实用方法.这些 2,2'-联吡啶带有多功能的官能团,可以进一步细化,如一些例子所示.(© Wiley-Vch Verlag Gmbh & Co. Kgaa,69451 Weinheim,Germany,2003)
Doi:10.1002/ejoc.200300192

专利信息

专利号:US-8598166-B2
优先权日:2008-03-21
标 题:Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof
发明人：DE PERETTI DANIELLE; EVANNO YANNICK; MACHNIK DAVID; RAKOTOARISOA NATHALIE
权利人:DE PERETTI DANIELLE; EVANNO YANNICK; MACHNIK DAVID; RAKOTOARISOA NATHALIE; SANOFI SA
摘要:Compounds of formula (I): n nwherein R 1 , R 2 , R 3 , R 4 , Het and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

专利号:US-7405310-B2
优先权日:2001-03-05
标 题:Non-nucleoside reverse transcriptase inhibitors
发明人：LINDSTROM STEFAN; SAHLBERG CHRISTER; WALLBERG HANS; KALYANOV GENAIDY; ODEN LOURDES SALVADOR; NAESLUND LOTTA
权利人:MEDIVIR AB
摘要:This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.

专利号:US-11731956-B2
优先权日:2018-10-22
标 题:Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

专利号:US-8865898-B2
优先权日:2010-11-30
标题:Nucleoside analog or salt thereof, oligonucleotide analog, gene expression inhibitor, and nucleic-acid probe for detecting gene
发明人：UENO YOSHIHITO
权利人:UENO YOSHIHITO; JAPAN SCIENCE & TECH AGENCY
摘要:A nucleoside analog and a salt thereof represented by any of the general formulae (1) to (10) below: n nwherein R 1 , R 2 , and R 3 are the same or different groups, and each of the R 1 , R 2 and R 3 is selected from a hydrogen atom, a protecting group for a functional group in nucleic acid synthesis, a phosphate group, a phosphate group protected by a protecting group in nucleic acid synthesis, and an activated phosphate group for solid phase synthesis; and Ar is one of an aromatic hydrocarbon group and a polyaromatic hydrocarbon group.

专利号:WO-2023071314-A1
优先权日:2021-10-29
标 题:Synthesis, preparation method and use of shp2 and cdk4/6 dual-target inhibitory compound

专利号:US-12331058-B2
优先权日:2021-10-29
标 题:SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same
发明人：WU XIAOXING; CHEN XIAOYU; LI WENQIANG; Shu Chengxia; LUO GUANGMEI; YANG KEXIN
权利人:UNIV CHINA PHARMA
摘要:The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three compounds of general formulas I-III and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. According to the present invention, a class of brand-new SHP2 and CDK4/6 dual-target inhibitors are prepared by means of a pharmacophore fusion and reasonable drug design method, so that the problems of drug resistance, poor drug effect, etc., of the existing SHP2 inhibitor and CDK4/6 inhibitor are solved; the great significance of the present invention is providing the first SHP2 and CDK4/6 dual-target inhibitor, which provides a basis for solving the problem of drug resistance of kinase and phosphatase in the later period.